Clinical trial Recruiting at 1 site Observational Ages 18 to 80 Women only

Comparing Minto and Eleveld remifentanil target-controlled infusion models during general anesthesia

Official title: Minto and Eleveld Remifentanil Target Controlled Infusion (TCI) Models: a Clinical Comparison Through qNOX and ANIi Reactions to Post-tetanic Count

Run by University of Padova · NCT07259291 · Data updated 2026-11-12

This study tests whether the newer Eleveld remifentanil infusion model gives similar effect-site concentrations for pain control as the commonly used Minto model in adults having general anesthesia with propofol.

Quick facts

Study typeObservational
Ages18 Years to 80 Years
SexWomen only
Enrollment100 (estimated)
SponsorUniversity of Padova
Academic / other
Locations1 site (Treviso)
StatusRecruiting
StartedNovember 25, 2025
Main results expectedDecember 30, 2026
Study endsDecember 30, 2026
Registry record updatedJune 8, 2026
Trial IDNCT07259291 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults scheduled for general anesthesia using target-controlled infusions of propofol (Eleveld model) and remifentanil (Minto or Eleveld) without neurological or psychiatric disease are ideal candidates.

Probably not a fit

Patients with neurological or psychiatric disorders, children, or anyone not receiving TCI of propofol and remifentanil are unlikely to benefit from this comparison.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Remifentanil, a short-acting opioid, is commonly delivered by target-controlled infusion (TCI) using pharmacokinetic/pharmacodynamic models to maintain a desired effect-site concentration. This observational study compares the routinely used Minto model with the more recently developed Eleveld model by recording predicted remifentanil effect-site concentrations (CeR) and correlating them with nociception measures including qNOX (CONOX monitor), Analgesia Nociception Index (ANI), and post-tetanic count during maintenance. Participants receive propofol TCI using the Eleveld propofol model and remifentanil via either the Minto or Eleveld remifentanil model while standard monitoring is performed. The goal is to determine whether the two models require different CeR to achieve similar analgesic/nociceptive readouts.

Why it matters

Potential benefit: If the Eleveld model better matches nociception signals, it could help clinicians dose remifentanil more accurately and reduce under- or over-dosing during anesthesia.

How similar studies have gone: The Minto model is well established in clinical practice while the Eleveld model is newer and based on large pooled datasets, but direct head-to-head clinical comparisons remain limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Undergo general anaesthesia with Targeted Controlled Infusion of Propofol (Eleveld model) and Remifentanil (Minto or Eleveld model)

Exclusion Criteria:

* Neurological disease
* Psychiatric disease

Where it's running

  • ULSS2 Marca Trevigiana
    Treviso, Italy
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.